Literature DB >> 29450606

Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone.

Amanda R Smolock1, Mircea M Cristescu1, Audrey Hinshaw1, Kaitlin M Woo2, Shane A Wells1, Timothy J Ziemlewicz1, Meghan G Lubner1, Prasad S Dalvie1, J Louis Hinshaw1, Christopher L Brace1,3,4, Orhan S Ozkan1, Fred T Lee1,3, Paul Laeseke5.   

Abstract

PURPOSE: To compare transarterial chemoembolization (TACE) monotherapy to combination TACE and microwave ablation (MWA) for local control of 3- to 5-cm hepatocellular carcinoma (HCC).
METHODS: Patients with HCC between 3 and 5 cm treated with TACE monotherapy or combination TACE + MWA at a single institution between 2007 and 2016 were retrospectively reviewed. Twenty-four HCCs (median diameter 3.8 cm) in 16 patients (13 males; median age 64 years) were treated using TACE monotherapy. Combination TACE + MWA was used to treat 23 HCCs (median diameter 4.2 cm) in 22 patients (18 males; median age 61 years). Microwave ablation was performed at a target time of two weeks following TACE. Individual tumors were followed by serial contrast-enhanced CT or MR. Response to treatment was evaluated on a tumor-by-tumor basis using mRECIST criteria with the primary outcome being local tumor progression (LTP). Data were analyzed using Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Time to LTP was estimated with the Kaplan-Meier method.
RESULTS: Relative to TACE monotherapy, TACE + MWA provided a trend toward both a lower rate of LTP (34.8% vs. 62.5%, p = 0.11) and a higher complete response rate (65.2% vs. 37.5%; p = 0.12). Time to LTP (22.3 months vs. 4.2 months; p = 0.001) was significantly longer in the TACE + MWA group compared to TACE monotherapy.
CONCLUSIONS: Combination therapy with TACE and microwave ablation improves local control and increases time to LTP for 3-5 cm HCC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29450606     DOI: 10.1007/s00261-018-1464-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  9 in total

1.  Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score.

Authors:  Zi-Yi Zhu; Mu Yuan; Pei-Pei Yang; Bo Xie; Jian-Zhu Wei; Zhong-Qiang Qin; Zhen Qian; Zhao-Ying Wang; Long-Fei Fan; Jing-Yu Qian; Yu-Lin Tan
Journal:  World J Surg Oncol       Date:  2022-06-10       Impact factor: 3.253

2.  Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead.

Authors:  John Reicher; Sebastian Mafeld; Georgia Priona; Helen L Reeves; Derek M Manas; Ralph Jackson; Peter Littler
Journal:  Cardiovasc Intervent Radiol       Date:  2019-08-27       Impact factor: 2.740

3.  Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.

Authors:  Zhen-Xin Chen; Zhi-Wei Jian; Xi-Wen Wu; Jun-Cheng Wang; Jing-Yuan Peng; Xiang-Ming Lao
Journal:  Cancer Med       Date:  2019-07-17       Impact factor: 4.452

4.  Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Zheng Li; Qiang Li; Xiaohu Wang; Weiqiang Chen; Xiaodong Jin; Xinguo Liu; Fei Ye; Zhongying Dai; Xiaogang Zheng; Ping Li; Chao Sun; Xiongxiong Liu; Qiuning Zhang; Hongtao Luo; Ruifeng Liu
Journal:  Cancer Med       Date:  2021-10-16       Impact factor: 4.452

5.  New approach for hepatocellular carcinoma treatment.

Authors:  Daniela Tabacelia; Cezar Stroescu; Radu Dumitru; Raluca Roxana Grigorescu; Alexandru Martiniuc; Ioana Alexandra Husar-Sburlan; Narcis Copca
Journal:  J Med Life       Date:  2022-01

Review 6.  Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?

Authors:  Zeno Sparchez; Pompilia Radu; Adrian Bartos; Iuliana Nenu; Rares Craciun; Tudor Mocan; Adelina Horhat; Mihaela Spârchez; Jean-François Dufour
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

Review 7.  Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria.

Authors:  Yanzhao Zhou; Yi Yang; Bingyan Zhou; Zhengzheng Wang; Ruili Zhu; Xun Chen; Jingzhong Ouyang; Qingjun Li; Jinxue Zhou
Journal:  J Hepatocell Carcinoma       Date:  2021-06-21

8.  Transarterial Chemoembolization and Sorafenib Combined with Microwave Ablation for Advanced Primary Hepatocellular Carcinoma: A Preliminary Investigation of Safety and Efficacy.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Jiang-Hong Luo; Xiong-Ying Jiang; Dong Chen; Wei-Dong Wang; Yao-Ting Chen; Jin-Hua Huang; Lin-Feng Xu
Journal:  Cancer Manag Res       Date:  2019-11-26       Impact factor: 3.989

9.  Association of Addition of Ablative Therapy Following Transarterial Chemoembolization With Survival Rates in Patients With Hepatocellular Carcinoma.

Authors:  Keara English; N Patrik Brodin; Viswanathan Shankar; Shaoyu Zhu; Nitin Ohri; Yosef S Golowa; Jacob Cynamon; Sarah Bellemare; Andreas Kaubisch; Milan Kinkhabwala; Shalom Kalnicki; Madhur K Garg; Chandan Guha; Rafi Kabarriti
Journal:  JAMA Netw Open       Date:  2020-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.